W. Ann Reynolds, Ph.D. Joins Invitrogen Corporation's Board of Direct

    Business Editors/Health/Medical Writers
    BIOWIRE2K

    CARLSBAD, Calif.--(BUSINESS WIRE)--Feb. 14, 2005--Invitrogen Corporation (Nasdaq:IVGN) today announced that W. Ann Reynolds, Ph.D. has joined its Board of Directors, effective Feb. 9, 2005. Dr. Reynolds led a distinguished career as the head of several prominent universities including the University of Alabama at Birmingham, the City University of New York, and the California State University system.
    "A critical part of our business is supporting the university research that ultimately drives innovation in the commercial biotechnology sector," said Gregory T. Lucier, Invitrogen's Chairman and CEO. "Dr. Reynolds' unique understanding of the academic setting, and science education in particular, makes her ideally suited to help guide our efforts to accelerate these important endeavors."
    The appointment increases the size of the Invitrogen board from nine to ten directors.
    Dr. Reynolds served as the President of the University of Alabama at Birmingham from 1997 to 2002. She was also the Chancellor of the City University of New York from 1990 to 1997, where she was responsible for the 21 colleges and professional schools that comprised that system. Before that, Dr. Reynolds was the Chancellor of the California State University system from 1982 to 1990, and held academic posts as clinical professor of obstetrics and gynecology at the UCLA School of Medicine. Earlier in her career, Dr. Reynolds held academic and administrative posts at Ohio State and the University of Illinois Medical Center.
    A native of Kansas, Dr. Reynolds holds Ph.D. and masters degrees in zoology from the University of Iowa, as well as a bachelors degree in biology from Emporia State University, Kansas. She was a National Science Foundation Predoctoral Fellow and an honorary Woodrow Wilson Fellow.

    About Invitrogen

    Invitrogen Corporation (Nasdaq:IVGN) provides products and services that support academic and government research institutions and pharmaceutical and biotech companies worldwide in their efforts to improve the human condition. The company provides essential life science technologies for disease research, drug discovery, and commercial bioproduction. Invitrogen's own research and development efforts are focused on breakthrough innovation in all major areas of biological discovery including functional genomics, proteomics, bioinformatics and cell biology -- placing Invitrogen's products in nearly every major laboratory in the world. Founded in 1987, Invitrogen is headquartered in Carlsbad, California and conducts business in more than 70 countries around the world. The company globally employs approximately 4,000 scientists and other professionals and had revenues of more than $1 billion in 2004. For more information, visit www.invitrogen.com

    Safe Harbor Statement

    Certain statements contained in this press release are considered "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, and it is Invitrogen's intent that such statements be protected by the safe harbor created thereby. Forward-looking statements include, but are not limited to: 1) Dr. Reynolds' guidance will help Invitrogen accelerate academic research. Potential risks and uncertainties include, but are not limited to, the risks: a) Dr. Reynolds' service on the Board of Directors may not impact Invitrogen's ability to accelerate academic research or innovation, as well as other risks and uncertainties detailed from time to time in Invitrogen's Securities and Exchange Commission filings.

--30--WAM/la*

CONTACT: Invitrogen Corporation Adam S. Taich, 760-603-7200 (Investors) Greg Geissman, 760-476-7032 (Media) gregory.geissman@invitrogen.com

KEYWORD: CALIFORNIA INDUSTRY KEYWORD: MEDICAL PHARMACEUTICAL BIOTECHNOLOGY MANAGEMENT CHANGES SOURCE: Invitrogen Corporation

Copyright Business Wire 2005